CLINICAL RESEARCH IN NEURO-ONCOLOGY

神经肿瘤学临床研究

• 批准号: 6665060
• 负责人: Roy Andrew Patchell
• 金额: $ 8.48万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-30 至 2005-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6665060
• 关键词: brain neoplasms; clinical research; drug delivery systems; human subject; medical education; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer education; role model; slow release drug; training

Dr. Roy A. Patchell's entire medical career has been devoted to patient oriented clinical Neuro-Oncology research. He completed a residency in Neurology at Johns Hopkins and a fellowship in clinical Neuro Oncology at Memorial Sloan-Kettering Cancer Center. He then came to the University of Kentucky and ha developed a comprehensive clinical Neuro-Oncology research program. This has involved the development of numerous clinical trials investigating the treatment of metastatic and primary brain tumors. On all of these studies, Dr. Patchell has been the principal investigator. He has had continuous extramural funding since 1986 and continuous RO1 NIH funding since 1988 and has a currently funded RO1 grant. All of his RO1 funding has been for clinical Neuro-Oncology trials. In addition to past and currently ongoing clinical trials assessing the effects of commonly available therapies for cancers of the nervous system, Dr. Patchell has invented an implantable, refillable, sustained-release device for the delivery of intratumoral chemotherapy for primary brain tumors. This device is currently being used in several phase I and phase II trials designed by Dr. Patchell, and one study has become a national trial under the auspices of the Radiation Therapy Oncology Group (RTOG). Dr. Patchell is continuing to collaborate with basic scientists at the University of Kentucky to investigate further uses of the device, including use with non-conventional agents such as anti-angiogenesis factors, biological response modifiers, radiation cell sensitizers, and other compounds. Dr. Patchell has a strong record of actively mentoring budding clinical investigators including residents, fellows, and junior faculty members at the University of Kentucky. In 1995, he established a Neuro-Oncology Fellowship Training Program and is currently training Neuro-Oncology Fellows. Dr. Patchell's careers goals include obtaining additional external funding so that he can expand the Neuro-Oncology Fellowship training program and continue to devote the majority of his time to mentoring his Neuro-Oncology Fellows and to developing new treatments for primary and metastatic brain tumors.

Roy A. Patchell博士的整个医疗生涯一直致力于以患者为导向的临床神经肿瘤学研究。他在约翰霍普金斯大学完成了神经病学住院医师学习，并在纪念斯隆-凯特琳癌症中心完成了临床神经肿瘤学研究。随后，他来到肯塔基大学，开发了一个全面的临床神经肿瘤学研究项目。这涉及到研究转移性和原发性脑肿瘤治疗的许多临床试验的发展。在所有这些研究中，帕切尔博士都是首席研究员。他自1986年以来连续获得校外资助，自1988年以来连续获得NIH资助，目前获得资助的RO1资助。他所有的RO1基金都用于临床神经肿瘤学试验。除了过去和目前正在进行的评估神经系统癌症常用疗法效果的临床试验外，Patchell博士还发明了一种可植入、可重复填充的缓释装置，用于原发性脑肿瘤的肿瘤内化疗。该设备目前正在由Patchell博士设计的几项I期和II期试验中使用，其中一项研究已成为放射治疗肿瘤小组（RTOG）主持的全国性试验。Patchell博士正在继续与肯塔基大学的基础科学家合作，研究该设备的进一步用途，包括与非传统药物如抗血管生成因子、生物反应调节剂、辐射细胞增敏剂和其他化合物一起使用。Patchell博士在肯塔基大学积极指导崭露头角的临床研究人员，包括住院医生、研究员和初级教员方面有着良好的记录。1995年，他建立了神经肿瘤学研究员培训计划，目前正在培训神经肿瘤学研究员。Patchell博士的职业目标包括获得额外的外部资金，这样他就可以扩大神经肿瘤学奖学金培训计划，并继续投入大部分时间指导他的神经肿瘤学研究员，并开发原发性和转移性脑肿瘤的新疗法。